US biotech major Biogen has entered into an agreement to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications, from Japan’s Mitsubishi Tanabe Pharma. 9 September 2015
Privately-held US firm Purdue Pharma says it has acquired VM-902A, a first-in-class, allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor, as well as the backup compounds and associated intellectual property for the potential treatment of chronic pain, from VM Pharma. 8 September 2015
Swedish pharma companies Recipharm and LobSor have formed a manufacturing agreement for Lecigon,a treatment for advanced Parkinson's disease. 8 September 2015
Addex Therapeutics on Tuesday said it has signed an early stage agreement with Pierre Fabre Pharmaceuticals in the field of central nervous system (CNS). 8 September 2015
Indian drugmaker Cipla has entered into definitive agreements to acquire two USA-based companies, InvaGen Pharmaceuticals and Exelan Pharmaceutics. 4 September 2015
ACADIA Pharmaceuticals has submitted a New Drug Application to the US Food and Drug Administration seeking approval for Nuplazid (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. 3 September 2015
Novartis and biotechnology firm Amgen have partnered to jointly develop new drugs for Alzheimer's disease. The collaboration is in line with the Swiss drugmakers strategy to develop a portfolio of treatments for neurological diseases. 2 September 2015
The US subsidiary of Japan’s Eisai and privately-held US firm Purdue Pharma have entered into a worldwide collaboration agreement for the development and commercialization of Eisai's clinical candidate lemborexant. 31 August 2015
USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese pharma major Sumitomo Dainippon Pharma, has received approval from the US Food and Drug Administration for the supplemental New Drug Application (sNDA) for Aptiom (eslicarbazepine acetate) as monotherapy for the treatment of partial-onset seizures. 30 August 2015
Acorda Therapeutics yesterday announced that the US Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) will not institute the inter partes review (IPR) of US Patent Nos 8,663,685 and 8,007,826. 25 August 2015
The results of a pivotal global Phase III study on Fycompa (perampanel) from Eisai in primary generalized tonic-clonic seizures showed that one third more patients treated with the drug experience a 50% responder rate, statistically significant versus placebo. 24 August 2015
GlaxoSmithKline has reached an agreement with a unit of Swiss peer Novartis to divest its rights in ofatumumab for auto-immune indications, including multiple sclerosis. 21 August 2015
Following evaluation of dossiers relating to CNS specialist Zambon and its partner, fellow Italy-based Newron Pharmaceuticals’ Parkinson’s disease drug Xadago (safinamide), the German Institute for Quality and Efficiency in Health Care (IQWiG) concluded that an added benefit cannot be derived versus comparator drugs from the dossier, because relevant study data were not considered and the analyses were therefore incomplete. 20 August 2015
Concordia Pharmaceuticals and Par Pharmaceutical have settled Federal Trade Commission charges that they entered into an unlawful agreement not to compete in the sale of generic versions of Kapvay (clonidine hydrochloride). 19 August 2015
Danish CNS specialist drugmaker Lundbeck (LUN: CO) this morning announced a major restructuring program which will reduce the total cost base by around 3 billion Danish kroner ($448 million) with full effect in 2017. 19 August 2015
Avanir Pharmaceuticals has received a favorable ruling from the US Court of Appeals regarding Nuedexta (dextromethorphan hydrobromide/quinidine sulfate). 19 August 2015
Mylan has confirmed that it has been sued by BTG and Johnson & Johnson subsidiaries in connection with the filing of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration for abiraterone acetate tablets, 250mg. 18 August 2015
Insys Therapeutic has filed a Citizen Petition with the US Drug Enforcement Administration to request the agency reschedule its synthetic pharmaceutical cannabidiol (CBD) from Schedule I to Schedule IV. 18 August 2015
The District Court for the Southern District of New York has issued a ruling upholding two Endo International patents covering its top-selling opioid analgesic Opana ER (oxymorphone hydrochloride). 15 August 2015
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024